In this episode of Denatured, you’ll hear from Lance Alstodt, chairman and CEO at Biorestorative Therapies, and Paul Mieyal, chief business officer at South Rampart Pharma. We explore why pain has remained such a difficult therapeutic area to tackle and one of the biggest unmet needs today, and how non-opioid mechanisms to regenerative therapies could reshape the future of treatment.Host<a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/jennifersmithparker/" target="_blank">Jennifer C. Smith-Parker</a>, Director of Insights, BioSpaceGuests<a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/lance-alstodt-b9951315/" target="_blank">Lance Alstodt</a>, Chairman &amp; CEO, BioRestorative Therapies<a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/paul-mieyal/" target="_blank">Paul Mieyal, </a>Chief Business Officer, South Rampart PharmaDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.